

#### **Update on WHO work**

Irena Prat
World Health Organization
Brasilia, 8-10 March 2016



## What's new since September 2015

- Prequalification of IVDs
- Zika and Ebola-related work
- Regulatory strengthening



#### **PQDx Dossiers**

- Positive trend: Dossier submissions quality is increasing
- Innovators and emerging manufacturers in general still struggle to meet basic requirements
- A number of manufacturers who failed in previous attempts are responding with greatly improved new submissions
- The lack of both general and product specific guidance remains a major issue



### PQDx Changes notification and assessment

- Reporting of changes to a WHO prequalified IVD in place since June 2014
- Result has been variable compliance and significant work load for PQDx
- Lack of substantive international guidance on changes/variations makes it difficult for manufacturers
- Updated WHO guidance adds granularity to ensure consistency and transparency in decision making process
  - Open for public comment until 31/03
- Need for international harmonized approach to changes

### **Technical Guidance Series and** Sample dossiers

WHO developing a technical guidance series (TGS) for manufacturers on issues considered of critical importance when developing and gathering data to support manufacturers' claims.

- Published in 2015 for public comment
  - TGS 1 Standards, TGS 2 Stability
- To be published Q1/Q2 2016
  - Instructions for use, Test method validation, Principles of performance studies, Kit component stability

WHO developing additional sample product dossiers for WHO prequalification of IVDs

- Published in 2015 for public comment
- Sample Product Dossier for an RDT intended for HIV self-testing.
- To be published Q1/Q2 2016
- Sample Product Dossier for a Qualitative NAT for HIV and a Quantitative 5 NAT for HIV



# Emergency Use Assessment and Listing Procedure for IVDs

- Still ongoing for Ebola IVDs
  - Need remains for quality IVDs for surveillance especially using oral fluid from cadavers
- An EOI was published on 5 Feb 2016 inviting manufacturers to submit to EUAL for Zika IVDs
- Meeting 14-16 March Geneva to finalise EUAL requirements and seek input from NRAs and NRLs
  - aim to achieve internationally harmonised requirements and cooperation
- Numerous companies have an interest in submitting
  - Shortage of specimens for validation remains a critical aspect

#### PQDx post-market surveillance

- Launch of WHO guidance on post-market surveillance for in vitro diagnostics in 2015 <a href="http://www.who.int/diagnostics\_laboratory/postmarket/en/">http://www.who.int/diagnostics\_laboratory/postmarket/en/</a>
- Continuation of WHO complaint handling procedure through standardized IVD complaint form
  - Positive reporting trend but much advocacy and capacity building still needed



### Model regulatory framework for medical devices: where are we

- Target audience established: regulatory authorities in countries with little or no regulation for medical devices in place
- Definition of a medical device and IVD as a medical device accepted: GHTF definitions
- Life cycle of a medical device: pre-market, placing on the market, post-market
- Stepwise approach: two levels: basic level and expanded
- Reliance is an important approach



#### DRF International Medical Device Regulators Forum

#### **LEGAL FRAMEWORK**

LEGAL FRAMEWORK		
ENFORCEMENT		
Expanded level controls		
Pre-market	Placing on the market	Post-market
In-country clinical trial oversight	Advertising and promotion controls	In-country dissemination of alerts
Issue guidelines	Criteria for reliance	Post-market surveillance including vigilance
Appoint and oversee CABs	In-country QMS audit	Testing lab
Recognize standards	Pre-market review of compliance with essential principles	Patient registries
Nomenclature		In-country inspection
Classification rules	Exemptions of regulatory requirements for public health emergencies	Inspection international
x		Exchange of alerts international
x	x	Monitor FSCA
Basic level controls		
Pre-market	Placing on the market	Post-market
* Definition of a medical device * Essential principles of quality, safety and performance * Classification of devices * Labelling and IFU (instruction for use) * Declaration of conformity * QMS * Reliance * Donations * Advertising * Authorized representative/ manufacturer/importer distributor * Transition period	* Listing of medical devices * Registration of establishments * Import controls	* Mandatory reporting death and serious injury * FSCA including recall * Market surveillance

#### Next steps

- First draft was discussed 9-10 February 2016
- Public Consultations Q1 and Q3 2016
- Adoption by Expert Committees (ECSPP and ECBS)
- Model Regulatory Framework for medical devices: 2016
- Implementation workshops 2016-2017
- Model will be used as basis for developing the NRA assessment tool for medical devices



#### Thank you